FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter

Dec 5

US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension

Dec 4

FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter

Dec 4

Dual Special Needs Plans (D-SNPs) and Key 2026 Changes: What Dual Eligibles Need to Know During Medicare Enrollment | iPharmaCenter

Dec 2

FDA Clears Imfinzi as First Perioperative Immunotherapy for Resectable Gastric and GEJ Cancers | iPharmaCenter

Dec 1

FDA Greenlights Kygevvi as Pioneering Therapy for Thymidine Kinase 2 Deficiency in Adults and Kids | iPharmaCenter

Nov 28

Novartis Receives FDA Approval for Itvisma, Expanding Access to Gene Replacement Therapy for People of All Ages Living with Spinal Muscular Atrophy (SMA)

Nov 25

FDA Approves KEYTRUDA and KEYTRUDA QLEX in Combination with Padcev as Perioperative Treatment for Cisplatin-Ineligible Muscle-Invasive Bladder Cancer | iPharmaCenter

Nov 23

FDA Approves Epkinly in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma | iPharmaCenter

Nov 19

FDA Approves Novartis' Pluvicto for Earlier Treatment of Prostate Cancer | iPharmaCenter

Apr 3

Tevimbra Receives U.S. Approval for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy | iPharmaCenter

Mar 5

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

Feb 3

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

Jan 29

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

Jan 3

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

Dec 23, 2024

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

Oct 13, 2024

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

Oct 13, 2024

US FDA Approved Opdivo as perioperative treatment in patients with resectable non-small cell lung cancer | iPharmaCenter

Oct 9, 2024

FDA Grants Accelerated Approval to Gilead’s Livdelzi for PBC, Marking Breakthrough in Liver Disease Treatment | iPharmaCenter

Aug 24, 2024

Novartis Gains FDA Accelerated Approval for Fabhalta (iptacopan), a Complement Inhibitor for Reducing Proteinuria in Primary IgA Nephropathy (IgAN)

Aug 8, 2024

FDA Approved Sun Pharma's Leqselvi (deuruxolitinib) for Severe Alopecia Areata

Aug 8, 2024

US FDA Approves Expanded Use of Jemperli Plus Chemotherapy for Endometrial Cancer

Aug 5, 2024

FDA Approves Lilly's Kisunla for Early Symptomatic Alzheimer's Disease

Jul 4, 2024

Imfinzi approved for mismatch repair deficient endometrial cancer, fifth indication for AZ's blockbuster | iPharmaCenter

Jun 20, 2024

FDA Approved Skyrizi for Ulcerative Colitis, Enhancing AbbVie's Inflammatory Bowel Disease Portfolio

Jun 19, 2024

FDA Approved Merck’s Keytruda Plus Chemotherapy for Advanced or Recurrent Endometrial Carcinoma

Jun 18, 2024

FDA Approved Bristol Myers Squibb’s Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma

May 31, 2024

FDA approved BMS' Breyanzi for relapsed or refractory follicular lymphoma | iPharmaCenter

May 16, 2024

FDA Grants Complete Approval for Tivdak in Treating Recurrent or Metastatic Cervical Cancer

Apr 30, 2024

FDA Drug Approvals | 2024 | iPharmaCenter

Apr 20, 2024

FDA approved Orchard Therapeutics' Lenmeldy for juvenile metachromatic leukodystrophy | FDA Approvals | News | iPharmaCenter

Mar 20, 2024

FDA Gives Green Light to First Medication for Individuals with Liver Scarring Stemming from Fatty Liver Condition | iPharmaCenter

Mar 16, 2024

2023 | FDA Drug Approvals | US Pharma News | iPharmaCenter

Dec 21, 2023

FDA Greenlights First Treatment for Uncommon Non-Cancerous Growth | FDA Approvals | iPharmaCenter

Nov 30, 2023

Chikungunya | Drugs | Vaccines | News | Updates | iPharmaCenter

Nov 18, 2023

Project Orbis News | Updates | Truqap approved in the US

Nov 18, 2023

FDA-Approved Chronic Weight Management Drug Zepbound, rival to Wegovy

Nov 12, 2023

UCB potential multi-billion blockbuster Bimzelx approved for plaque psoriasis | FDA | iPharmaCenter

Oct 18, 2023

Pfizer's Abrysvo approved in US to prevent RSV infection in infants |iPharmaCenter

Aug 22, 2023

Pfizer's Elrexfio approved for heavily pretreated multiple myeloma patients | iPharmaCenter

Aug 14, 2023

FDA gave nod for Zurzuvae to treat postpartum depression but NO to major depressive disorder

Aug 5, 2023

FDA Approved RSV treatments | iPharmaCneter

Jul 17, 2023

BioMarin Pharmaceutical's $2.9 million gene therapy Roctavian was approved for haemophilia A

Jun 29, 2023

FDA Approved diabetic treatments | 2023 |

Jun 28, 2023

FDA Approved Myasthenia gravis treatments | News | Updates | iPharmaCenter

Jun 27, 2023

US FDA approved drugs for Duchenne Muscular Dystrophy | Elevidys | Viltepso | iPharmaCenter

Jun 23, 2023

FDA News and Updates | US Pharma News | iPharmaCenter

Jun 21, 2023

2022 FDA Drug Approvals | US Pharma News | iPharmaCenter

Feb 7, 2023

US FDA Withdrawals | News | Blenrep was withdrawn from the US market | iPharmaCenter

Nov 23, 2022

US FDA approved BMS Sotyktu (deucravacitinib) for moderate to severe plaque psoriasis |iPharmaCenter

Sep 11, 2022